Summary & Overview
HCPCS Q5155: Aflibercept-jbvf (yesafili) Injection, 1 mg
HCPCS Level II code Q5155 designates a 1 mg dose of aflibercept-jbvf (yesafili), a biosimilar intravitreal anti-VEGF injection. This code captures administration of a biosimilar therapeutic used in ophthalmic care for retinal vascular diseases and is relevant nationally as biosimilar adoption can affect utilization patterns and drug spending across outpatient eye-care settings. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what the code represents clinically, where the service is typically provided, and which major national payers cover or adjudicate claims for this product. The publication outlines benchmarks for use, policy and coverage considerations that commonly accompany biosimilar injections, and operational implications for billing and coding in ophthalmology clinics and ambulatory surgical centers. Data not available in the input will be noted where applicable, and the report focuses on national-level context rather than state-specific guidance.
Billing Code Overview
HCPCS Level II code Q5155 represents the injection of aflibercept-jbvf (yesafili), biosimilar, 1 mg. This procedure is a biologic intravitreal injection used in ophthalmology to treat retinal vascular conditions that respond to anti-VEGF therapy.
-
Service type: Intravitreal biologic injection
-
Typical site of service: Ophthalmology clinic or ambulatory surgical center with procedures performed in an outpatient eye-care setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult with neovascular (wet) age-related macular degeneration or diabetic macular edema presenting to an ophthalmology clinic for an intravitreal anti-VEGF injection. The patient is pre-screened by the retina specialist or clinical staff for visual acuity, intraocular pressure, and history of recent ocular infection or systemic contraindications. After informed consent, the patient is positioned in a minor procedure room or clinic procedure area. Topical anesthesia and antisepsis (povidone-iodine) are applied, and a sterile eyelid speculum is placed. A measured dose of Q5155 (injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg) is prepared by pharmacy or clinic staff following safe handling and labeling protocols. The retina specialist performs the intravitreal injection through the pars plana, monitors for immediate complications, and documents laterality, lot number, and vaccine-specific details. Post‑procedure care includes intraocular pressure check, activity restrictions, and instructions for signs of endophthalmitis. Typical site of service is an ophthalmology clinic procedure room or ambulatory surgical center when combined with other surgical services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased Procedural Services | Use when work required to administer the injection is substantially greater than typically required (rare for standard intravitreal injections; may apply if significant additional, documented work is performed). |